• Two additional clinicians appointed to AdCella's clinical advisory board
• The advisory board now represents five potential clinical sites for the first clinical trial of BZDS1901 in Australia
• Advisory board members bring deep expertise in clinical oncology, mesothelioma, immunology, haematology and CAR-T cell therapy

AdAlta Limited (ASX:1AD), developer of next generation cell and protein therapeutic products, advises that its subsidiary, AdCella Pty Ltd ('AdCella') has appointed two additional clinicians to its clinical advisory board to advise on clinical development and Phase 1 trial design of BZDS1901, its mesothelin-targeted, armoured CAR-T cell therapy developed to treat mesothelioma and other solid cancers, including lung and gynaecological malignancies. The appointments of Nick Pavlakis and Mark Shackleton strengthen the expertise of the advisory board in clinical oncology, mesothelioma, solid cancer CAR-T cell therapies, haematology and immunology, which are all necessary to safely and efficiently deliver BZDS1901 to patients with solid tumours. The role of the clinical advisory board is to review and advise on the clinical trial design for BZDS1901; advise on current and emerging treatment standards to best position BZDS1901 in the mesothelioma treatment algorithm; to identify new and emerging knowledge in mesothelioma and other tumours that may be targeted with BZDS1901; and to provide insights into leading international clinical institutes and thought leaders who can help with subsequent stages of development of the product. Combined, AdCella's clinical advisory board now covers five hospital systems already administering commercial CAR-T products in Australia who could become clinical trial sites for BZDS1901.